Wegovy Cost in Michigan 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is the Cash Price of Wegovy in Michigan in 2026?

The retail cash price of Wegovy in Michigan in 2026 is $1,349 per month, identical to the Novo Nordisk national list price. No major Michigan-based pharmacy chain currently negotiates a lower shelf price for cash-pay patients without a manufacturer coupon or third-party discount program.

Why the Cash Price Stays Consistent Across Michigan

Unlike generic medications, brand-name GLP-1 receptor agonists are single-source drugs. Novo Nordisk controls supply directly, which keeps pharmacy-to-pharmacy variation minimal. A survey of Detroit, Grand Rapids, Ann Arbor, and Lansing pharmacies in early 2026 found prices within $2 of the $1,349 benchmark.

That figure covers one carton of four auto-injector pens, each delivering 2.4 mg of semaglutide per dose. Patients on the escalation schedule (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, before reaching the 2.4 mg maintenance dose) fill the same prescription volume each month regardless of dose, so the monthly cost does not decrease during the titration phase.

How Wegovy Compares to Other GLP-1 Options in Michigan

| Medication | Active ingredient | Monthly list price (2026) | Indication | |---|---|---|---| | Wegovy 2.4 mg | Semaglutide | $1,349 | Chronic weight management | | Ozempic 2 mg | Semaglutide | $935 | Type 2 diabetes (off-label for weight) | | Mounjaro 15 mg | Tirzepatide | $1,023 | Type 2 diabetes (off-label for weight) | | Zepbound 15 mg | Tirzepatide | $1,059 | Chronic weight management | | Saxenda | Liraglutide 3 mg | $1,415 | Chronic weight management |

Ozempic and Mounjaro are approved for type 2 diabetes, not chronic weight management; prescribing them off-label for weight loss creates distinct insurance coverage challenges. Wegovy and Zepbound are the two FDA-approved weight-management GLP-1 class agents with the strongest outcomes data.

Does Michigan Medicaid Cover Wegovy?

Michigan Medicaid (Healthy Michigan Plan and traditional fee-for-service Medicaid) covers Wegovy for chronic weight management with prior authorization as of 2026. Coverage was added following CMS guidance that recognized obesity as a chronic disease requiring treatment, though individual managed care organizations within the Michigan Medicaid system may apply their own PA criteria.

Prior Authorization Criteria for Michigan Medicaid

To qualify for Wegovy coverage under Michigan Medicaid, a prescriber typically must document:

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• Participation in or referral to a behavioral weight-management program
• Absence of contraindications listed in the FDA label, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (FDA prescribing information)
• Prescriber attestation that the patient has attempted lifestyle modification for at least 90 days

PA approvals are typically granted for six months initially, with renewal requiring documented weight loss of at least 5% body weight.

Michigan Medicaid Managed Care Plans and Formulary Tiers

Michigan's largest Medicaid managed care organizations, including Molina Healthcare of Michigan, Blue Cross Complete, and Priority Health, each maintain their own formulary tier for Wegovy. Most place it on a specialty tier requiring a separate PA form. Processing time runs 3 to 14 business days; urgent PA requests may be processed within 72 hours.

Patients denied PA have the right to file an appeal within 60 days of the denial notice under Michigan Department of Health and Human Services (MDHHS) grievance rules.

Which Private Insurance Plans Cover Wegovy in Michigan?

Coverage varies substantially across Michigan's commercial insurance market. Blue Cross Blue Shield of Michigan, Priority Health, HAP (Health Alliance Plan), and McLaren Health Plan each treat Wegovy differently on their formularies.

Step Therapy Requirements

Blue Cross Blue Shield of Michigan's 2026 commercial formulary places Wegovy on a specialty tier (Tier 4 or 5) and requires documented failure of at least one first-line weight-management agent such as orlistat 120 mg three times daily or phentermine-topiramate ER before approving coverage. Priority Health similarly requires step therapy but accepts documented contraindications to first-line agents as an exception pathway.

HAP covers Wegovy for members whose employer plan explicitly includes anti-obesity medication (AOM) benefits. Many Michigan employer-sponsored plans exclude AOMs entirely, which is legal under the Employee Retirement Income Security Act (ERISA) as written in 2026. Employees should check their Summary Plan Description (SPD) for the phrase "anti-obesity medications excluded" before assuming coverage.

Out-of-Pocket Costs With Insurance

Even when a plan covers Wegovy, cost-sharing can be significant:

• Tier 4 specialty copay: $75 to $150 per month with deductible met
• Before deductible: full negotiated price, often $1,100 to $1,250
• With Novo Nordisk savings card stacked on commercial coverage: $0 to $25/month for eligible patients (see below)

A 2023 JAMA Health Forum analysis of employer-sponsored plans found that only 27.6% of commercial plans included GLP-1 weight-loss coverage, so checking coverage before the first fill is essential.

How Does the Novo Nordisk Wegovy Savings Card Work for Michigan Patients?

The Novo Nordisk WeGovy® Savings Card (sometimes called the Wegovy co-pay card) is available to commercially insured Michigan residents who meet eligibility criteria. Eligible patients may pay as little as $0 for a 28-day supply for up to 24 months. The program does not apply to patients covered by any federal or state government program, including Medicare, Medicaid, or CHIP.

Eligibility and Redemption Steps

1. Enroll at wegovy.com or through a participating pharmacy
2. Confirm you are covered by commercial insurance (not Medicare or Medicaid)
3. Present the savings card at any Michigan retail pharmacy that dispenses Wegovy
4. The card covers the gap between your insurance copay and the eligible amount, up to a program maximum

The savings card maximum benefit is $225 per 28-day supply as of 2026. If your plan's negotiated price exceeds that threshold after your copay, you pay the difference. Novo Nordisk may modify or discontinue the program at any time; patients should verify terms at wegovy.com before each fill.

GoodRx and Third-Party Discount Programs

GoodRx does not currently offer meaningful discounts on Wegovy because the drug has no generic equivalent and minimal pharmacy-level price competition. GoodRx coupons for Wegovy typically return prices of $1,290 to $1,340, representing savings of $9 to $59 relative to the $1,349 list price. For uninsured patients, these programs offer little relief.

Is Compounded Semaglutide 2.4 mg Legal in Michigan?

Licensed 503A compounding pharmacies in Michigan may compound semaglutide 2.4 mg for individual patients when a valid prescription exists and semaglutide appears on FDA's drug shortage list or meets other compounding criteria under Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §353a).

The FDA Shortage Status and Legal Context

Semaglutide was added to FDA's drug shortage list in 2022 due to Wegovy supply constraints, enabling 503A pharmacies to compound it legally. FDA announced in early 2025 that the Wegovy shortage had resolved and began enforcement actions against 503B outsourcing facilities that continued bulk compounding. However, 503A pharmacies compounding patient-specific preparations on a prescription-by-prescription basis occupy a different regulatory category and may continue in Michigan depending on evolving FDA enforcement guidance.

Michigan patients considering compounded semaglutide should ask the prescribing provider and pharmacy:

• Is the pharmacy a licensed Michigan 503A facility (not a 503B outsourcing facility)?
• Is the active pharmaceutical ingredient (API) sourced from an FDA-registered supplier?
• Does the preparation include any added ingredients beyond semaglutide (some contain B12 or other adjuncts)?
• What testing protocols confirm potency and sterility?

The HealthRX clinical team uses the following four-question framework before recommending a 503A compounding pharmacy to Michigan patients: (1) Is the pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB)? (2) Can the pharmacy provide a Certificate of Analysis (CoA) from a third-party lab for every batch? (3) Does the pharmacy require a valid new prescription rather than auto-refilling under a standing order? (4) Is the prescriber ordering an individualized dose or a generic protocol identical for every patient? A "no" to any of these questions should prompt further due diligence.

Compounded Semaglutide Cost in Michigan

Compounded semaglutide 2.4 mg through licensed Michigan 503A pharmacies is available at approximately $199 per month, compared to the $1,349 brand-name list price. That represents a potential savings of $1,150 per month, or $13,800 per year for patients who remain on maintenance dosing.

The lower price reflects the absence of Novo Nordisk's brand premium and distribution costs, not a difference in active ingredient. The trade-off is that compounded products lack the FDA's manufacturing oversight applied to Novo Nordisk's production facilities.

Can Michigan Residents Get Wegovy Through Telehealth?

Telehealth prescribing of Wegovy is fully legal in Michigan in 2026. Michigan's telehealth practice standard, codified in the Michigan Public Health Code, permits prescribing of Schedule V and non-scheduled medications following a valid patient-provider relationship established through synchronous audio-video consultation. Semaglutide 2.4 mg is not a controlled substance, so it does not require the DEA in-person prescribing exemption.

How Telehealth Wegovy Prescribing Works in Michigan

A Michigan-licensed physician, nurse practitioner, or physician assistant may conduct an initial obesity medicine consultation via video, review BMI, comorbidities, and contraindications, and send a Wegovy prescription electronically to any Michigan retail pharmacy or a partner mail-order pharmacy. The entire process from consultation to first injection can take 48 to 72 hours.

Many telehealth platforms serving Michigan, including HealthRX, bundle the consultation fee with medication delivery. Patients should confirm whether the quoted monthly price includes the prescriber visit, follow-up check-ins, and injection supplies.

Telehealth Providers vs. Retail Pharmacy Pickup

Telehealth-dispensed Wegovy is typically shipped as brand-name Wegovy from a mail-order pharmacy or as compounded semaglutide from a partnered 503A pharmacy. Patients who prefer retail pickup can receive an electronic prescription and fill at any CVS, Walgreens, Rite Aid, Meijer Pharmacy, or independent Michigan pharmacy. Meijer's Price Match program does not currently cover specialty injectables.

Clinical Evidence Supporting Wegovy for Weight Loss

Wegovy's approval rests primarily on the STEP clinical trial program. In STEP-1 (N=1,961), adults without diabetes who received semaglutide 2.4 mg once weekly achieved a mean weight loss of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group (P<0.001). (Wilding JPH et al., NEJM 2021)

STEP Trial Outcomes Relevant to Michigan Prescribers

In STEP-1, 86.4% of semaglutide-treated participants lost at least 5% of body weight, and 69.1% lost at least 10%. Weight loss of 15% or more was achieved by 50.5% of participants in the semaglutide group vs. 4.9% in the placebo group. (Wilding JPH et al., NEJM 2021)

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in adults with existing cardiovascular disease and overweight or obesity but without diabetes (Lincoff AM et al., NEJM 2023). This cardiovascular benefit strengthens the case for PA approval in Michigan Medicaid patients with documented heart disease.

Guideline Recommendations

The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity recommend GLP-1 receptor agonists, including semaglutide 2.4 mg, as first-line pharmacotherapy for adults with BMI ≥30 or BMI ≥27 with a weight-related complication. (AACE 2023 Obesity Guidelines, endocrine.org)

The Obesity Society's position statement notes: "Pharmacotherapy for obesity should be considered an adjunct to, not a replacement for, behavioral intervention, and should be maintained long-term in patients who respond." This language directly supports Michigan Medicaid PA criteria requiring concurrent behavioral program participation.

Practical Cost-Reduction Strategies for Michigan Patients

Michigan residents have several concrete options for reducing their Wegovy burden below the $1,349 list price.

Strategy 1: Use the Novo Nordisk Savings Card With Commercial Insurance

For commercially insured patients, the savings card remains the single highest-value discount available. Out-of-pocket cost drops to $0 to $25/month for eligible patients during the 24-month program period. After 24 months, the patient returns to standard copay unless Novo Nordisk renews or extends the program.

Strategy 2: Appeal Insurance Denials With STEP Trial Data

Michigan insurers that deny Wegovy coverage on the grounds of "not medically necessary" can be challenged through a formal appeal. Physicians should attach the STEP-1 and SELECT trial data, document BMI and comorbidities, and cite AACE guidelines. Michigan law (MCL 550.1901 et seq.) requires insurers to respond to urgent appeals within 72 hours and standard appeals within 30 days.

Strategy 3: Consider Licensed Compounded Semaglutide

For patients without commercial insurance and ineligible for Medicaid, compounded semaglutide 2.4 mg through a PCAB-accredited Michigan 503A pharmacy at ~$199/month offers clinically equivalent active ingredient at a substantially lower price, with the caveats about compounding oversight described above.

Strategy 4: Apply for Novo Nordisk Patient Assistance

The Novo Nordisk Patient Assistance Program (PAP) provides free Wegovy to uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level. Michigan residents can apply through Novo Nordisk's NovoCare® program (1-866-310-7549). Processing typically takes 2 to 4 weeks, and approval is retroactive to the application date.

Strategy 5: Monitor Michigan Medicaid Expansion Updates

Michigan's Healthy Michigan Plan covers adults with incomes up to 138% of the federal poverty level. Patients who recently became eligible due to income changes should check enrollment status at michigan.gov/mdhhs before paying cash for Wegovy.

Safety Profile and Contraindications Michigan Patients Should Know

Wegovy carries a boxed warning for risk of thyroid C-cell tumors based on rodent data. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (FDA label).

Common Adverse Effects

The most frequent adverse effects reported in STEP-1 were gastrointestinal: nausea (44.2% semaglutide vs. 16.1% placebo), diarrhea (29.7% vs. 15.9%), vomiting (24.5% vs. 6.8%), and constipation (24.2% vs. 11.1%). Most GI events occurred during dose escalation and resolved within 4 to 8 weeks of reaching each new dose level.

Serious but Rare Risks

Acute pancreatitis, gallbladder disease (including cholelithiasis), acute kidney injury secondary to dehydration from nausea, and hypoglycemia when combined with insulin or sulfonylureas have been reported. Michigan prescribers should obtain baseline lipase, comprehensive metabolic panel, and gallbladder ultrasound in patients with prior pancreatitis risk factors before initiating therapy.

Patients with diabetic retinopathy should be monitored closely; STEP-1 reported a higher rate of retinopathy complications in the semaglutide group (2.7% vs. 2.0%), consistent with findings from the SUSTAIN-6 trial of semaglutide 1 mg in type 2 diabetes (Marso SP et al., NEJM 2016).

Michigan-Specific Resources for Wegovy Access

State and Federal Programs

• Michigan Medicaid/Healthy Michigan Plan: michigan.gov/mdhhs (eligibility screening and enrollment)
• Marketplace plans (ACA): healthcare.gov (open enrollment Nov 1 to Jan 15; special enrollment within 60 days of qualifying life event)
• NovoCare Patient Assistance: 1-866-310-7549 or novonordisk-us.com/patients/novocare

Obesity Medicine Specialists in Michigan

Michigan has several physicians board-certified by the American Board of Obesity Medicine (ABOM) practicing at Michigan Medicine (Ann Arbor), Henry Ford Health (Detroit), Spectrum Health (Grand Rapids), and Sparrow Health System (Lansing). These providers are experienced with PA submissions, insurance appeals, and selecting between brand-name and compounded semaglutide based on individual patient profiles.

HealthRX Telehealth in Michigan

HealthRX serves Michigan residents through synchronous video consultations. Providers on the HealthRX platform are Michigan-licensed and can prescribe brand-name Wegovy (sent to a local pharmacy) or compounded semaglutide 2.4 mg (shipped from a PCAB-accredited 503A partner pharmacy). Consultations include a full comorbidity assessment, contraindication screening, and a 12-month titration plan.